Precigen Shares Fall After FDA Clears Inovio Immunotherapy
Precigen shares dropped 27 percent in after-hours trading after the U.S. Food and Drug Administration granted accelerated approval to Inovio Pharmaceuticals‘ Voceryq for adult recurrent respiratory papillomatosis, [finance.yahoo.com] reported. The decision introduces direct competition for Precigen’s PAPZIMEOS, which has served as the established commercial immunotherapy for the rare condition since its own approval in August 2025. Recurrent respiratory papillomatosis causes wart-like growths along the respiratory tract, most frequently on the vocal cords, and leaves patients dependent on repeat surgical removals because no cure exists.
Sales Figures Highlight Market Shift for Precigen and Inovio
Voceryq represents Inovio’s first approved product and relies on a plasmid DNA-based immunotherapy to target the human papillomavirus strains responsible for airway growths. The accelerated approval was backed by an open-label trial of 32 adults, which showed that 27 percent of participants with a high baseline surgery burden required no surgical interventions during the first year following treatment. The FDA mandates additional post-approval studies to confirm clinical benefit. Meanwhile, Inovio stock surged over 300 percent in after-hours trading following the announcement, whereas the company’s broader drug pipeline remains investigational.
Precigen $pgen overreaction to the $ino news. Their drug was not approved like Precigen’s is. Inovio still has work to do 👇“The agency based this accelerated approval on clinical trial data showing Voceryq helps reduce the frequency of surgical procedures required to remove…”
Commercial Standing of PAPZIMEOS Faces New Pressures
Precigen relies heavily on PAPZIMEOS as its sole approved product. The drug generated $3.4 million in net product sales during 2025 following shipments that began in November, contributing to total revenues of approximately $9.7 million for that year. Sales accelerated sharply into the first half of 2026, with Precigen reporting $74.7 million in net product sales for PAPZIMEOS out of $78.2 million in total revenue. The entry of Voceryq challenges this revenue concentration.
Retail Trader Reactions and Stock Performance Diverge
Stocktwits data captured a stark contrast in retail investor sentiment following the regulatory decision. Sentiment surrounding Precigen remained in bullish territory over a 24-hour window, accompanied by high message volume, while Inovio attracted extremely bullish sentiment and extremely high retail chatter. Stocktwits users debated the commercial runway for both firms, noting that Inovio faces extensive post-approval studies under its accelerated clearance while Precigen maintains full approval for its treatment. Year-to-date market performance also reflects a divergence, with Inovio stock down 65 percent and Precigen shares up 66 percent.
Frequently Asked Questions About the New Treatment Approval
What is recurrent respiratory papillomatosis and how does it affect patients?
Recurrent respiratory papillomatosis is a rare disease characterized by wart-like growths along the respiratory tract, particularly in the voice box and vocal cords. Because there is no cure, patients frequently undergo multiple surgeries to remove the obstructing growths and maintain breathing and speech functions.
What clinical evidence supported the FDA approval of Voceryq?
The FDA granted accelerated approval to Inovio’s Voceryq based on an open-label clinical trial involving 32 adult patients. Among participants who entered the study with a heavy surgery burden, 27 percent did not require any surgical interventions during the first year after receiving the plasmid DNA-based immunotherapy.
How does Voceryq compare to Precigen’s PAPZIMEOS in the market?
Precigen’s PAPZIMEOS received full FDA approval in August 2025 and brought in $74.7 million in net product sales during the first half of 2026. Inovio’s Voceryq gained accelerated approval as a competing immunotherapy, requiring subsequent post-approval studies to confirm its clinical benefit while immediately altering the competitive landscape for adult recurrent respiratory papillomatosis treatments.
Related reading